Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CATEGORY IIIB ALLERGENIC EXTRACTS LICENSES BEING REVOKED BY FDA

Executive Summary

CATEGORY IIIB ALLERGENIC EXTRACTS LICENSES BEING REVOKED BY FDA via a Nov. 16 Federal Register notice. The notice comes almost a decade after FDA classified approximately 280 generic allergens as Category IIIB, designating "those products with insufficient data and an unfavorable benefit-to-risk potential which the [Panel on Review of Allergenic Extracts] believed should not continue to be marketed during the development of data to resolve whatever safety and effectiveness questions exist." The Nov. 16 notice revokes the licenses for all Category IIIB products for which no sponsors have requested a hearing.

You may also be interested in...



Allergenic Extract Data Search Parameters Should Be Widened, Cmte. Says

FDA should expand its data search boundaries for the reclassification of allergenic extracts, its Allergenic Products Advisory Committee said

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel